Compare ACU & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACU | TNXP |
|---|---|---|
| Founded | 1867 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.1M | 172.7M |
| IPO Year | 1994 | 2008 |
| Metric | ACU | TNXP |
|---|---|---|
| Price | $44.44 | $13.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.7K | ★ 419.1K |
| Earning Date | 04-24-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | 1.63 | ★ 91.75 |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $196,541,816.00 | $13,107,000.00 |
| Revenue This Year | $5.72 | $558.11 |
| Revenue Next Year | $5.19 | $38.29 |
| P/E Ratio | $17.99 | ★ N/A |
| Revenue Growth | 1.05 | ★ 29.85 |
| 52 Week Low | $35.50 | $11.60 |
| 52 Week High | $47.31 | $69.65 |
| Indicator | ACU | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 46.22 |
| Support Level | $40.48 | $13.32 |
| Resistance Level | $46.89 | $20.36 |
| Average True Range (ATR) | 1.33 | 1.18 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 51.08 | 37.93 |
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.